Retatrutide (GLP-3): The Triple Agonist Peptide

Retatrutide (GLP-3): The Triple Agonist Peptide — A Research Overview

Retatrutide is a synthetic triple hormone receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors — currently the most advanced compound in the incretin research class. Developed by Eli Lilly under the code LY3437943, retatrutide has now progressed through Phase 3 clinical trials with landmark results published between December 2025 and May 2026, positioning it as one of the most closely watched metabolic research compounds in modern pharmacology.

For researchers studying metabolic regulation, energy homeostasis, and adipose tissue biology, retatrutide offers a mechanistically distinct and increasingly well-characterized research subject.

What Is Retatrutide?

Retatrutide (also known as LY3437943) is a synthetic peptide designed to simultaneously agonize three metabolic hormone receptors — GLP-1R, GIPR, and GcgR — representing a pharmacological approach that goes substantially further than first-generation GLP-1 receptor agonists. The compound was developed by Eli Lilly through structural modifications that enable balanced activity across all three receptors while providing an extended half-life supporting weekly research administration.

1. GLP-1R — Glucagon-like peptide-1 receptor
2. GIPR — Glucose-dependent insulinotropic polypeptide receptor
3. GcgR — Glucagon receptor

This triple receptor agonism is what distinguishes retatrutide from its predecessors in the GLP class. Semaglutide (Ozempic/Wegovy) is a GLP-1 monoagonist. Tirzepatide (Mounjaro) is a GLP-1/GIP dual agonist. Retatrutide adds glucagon receptor agonism to that combination — a third mechanism with distinct metabolic implications, particularly for energy expenditure.

The informal designation "GLP-3" used in the research community is not an official receptor nomenclature but rather a shorthand reflecting retatrutide's position as the third generation of GLP-class metabolic peptides. For a deeper mechanism explanation, see How Does Retatrutide Work? Understanding Triple Hormone Receptor Agonists.

Molecular specifications

• Developer Code: LY3437943
• Receptor Targets: GLP-1R, GIPR, GcgR (triple agonist)
• Molecular Weight: ~4,883 Da
• Half-life (in vivo): ~6 days (designed for weekly dosing in clinical studies)
• Form: Lyophilized powder
• Purity: ≥98–99%

The Three Receptors: What Each One Does

Each of retatrutide's three target receptors produces distinct biological effects — GLP-1R drives insulin secretion and appetite suppression, GIPR enhances insulin sensitivity and adipose effects, and GcgR increases energy expenditure through thermogenesis and fat oxidation. The pharmacological insight underlying retatrutide's design is that balanced engagement across all three receptors produces integrated metabolic effects that no single or dual agonist can achieve.

GLP-1R (Glucagon-Like Peptide-1 Receptor)

GLP-1 is an incretin hormone secreted by L-cells in the small intestine in response to food intake. Its receptor (GLP-1R) is expressed in the pancreas, brain, gastrointestinal tract, and heart, among other tissues.

GLP-1R agonism produces:

• Glucose-dependent insulin secretion (insulin released only when glucose is elevated)
• Suppression of glucagon secretion
• Delayed gastric emptying (contributing to satiety)
• Reduced appetite via central nervous system signalling in hypothalamic nuclei
• Potential cardiovascular protection (observed in clinical trials of GLP-1 agonist drugs)

This receptor is the foundation of the entire GLP drug class, from exenatide to semaglutide.

GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor)

GIP is the other major incretin hormone, secreted by K-cells in the duodenum. Like GLP-1, it enhances glucose-dependent insulin secretion. For years, GIPR agonism was considered a less useful target because GIP's insulinotropic effect is blunted in type 2 diabetes.

The addition of GIPR agonism in tirzepatide — and subsequently retatrutide — was initially counterintuitive but has produced markedly superior metabolic outcomes in clinical research compared to GLP-1 monoagonism alone. The mechanism of this synergy is an active area of investigation. Hypotheses include GIPR-mediated enhancement of GLP-1R sensitivity and independent adipose tissue effects of GIPR agonism.

GIPR is also expressed in bone tissue and the central nervous system, giving it research relevance beyond pure metabolic biology.

GcgR (Glucagon Receptor)

Glucagon is the counter-regulatory hormone to insulin — it raises blood glucose by stimulating hepatic glucose production and glycogenolysis. Adding glucagon receptor agonism to an already insulin-sensitizing compound might appear contradictory.

The rationale is energy expenditure. Glucagon receptor agonism increases:

• Basal metabolic rate
• Thermogenesis (heat production from brown adipose tissue)
• Hepatic fat oxidation
• Fatty acid oxidation in skeletal muscle

The key insight is that when glucagon receptor agonism is combined with GLP-1R agonism (which counters glucagon's glucose-raising effects), the net glycaemic outcome remains favourable while the metabolic-rate and fat-oxidation benefits of glucagon are preserved. This combination is what gives retatrutide its distinctive energy expenditure profile in research models.

Preclinical Research

Preclinical studies with retatrutide have consistently demonstrated superior metabolic effects compared to GLP-1 monoagonists across obesity, diabetes, and NASH rodent models — providing the mechanistic foundation for its subsequent clinical development. Animal research has particularly focused on diet-induced obesity, type 2 diabetes rodent models, and non-alcoholic steatohepatitis (NASH) models.

Key findings from animal studies

• Superior body weight reduction compared to GLP-1 monoagonists in diet-induced obese rodent models
• Significant reduction in hepatic fat content in NASH models, suggesting relevance for metabolic liver disease research
• Improvements in lipid profiles (triglycerides, LDL cholesterol) beyond what was observed with GLP-1 monoagonism alone
• Evidence of increased energy expenditure — supporting the glucagon receptor-mediated thermogenesis hypothesis

Clinical Research Timeline (Updated Through 2026)

Retatrutide has now progressed through Phase 3 clinical trials with three major readouts between December 2025 and May 2026, representing the most advanced clinical development of any triple hormone receptor agonist to date. The compound's clinical program under Eli Lilly's TRIUMPH designation continues through 2026, with regulatory submission expected Q4 2026 to Q1 2027.

Phase 1 (2022)

Dose-escalation studies in adults with obesity and type 2 diabetes established initial safety and pharmacokinetics data. The Phase 1b trial was published in The Lancet in 2022, confirming the compound's half-life supported weekly administration.

Phase 2 (2023 — published in New England Journal of Medicine)

A landmark 48-week randomized controlled trial enrolled 338 adults with obesity (no diabetes). At the highest dose studied, subjects receiving retatrutide lost an average of approximately 24% of body weight — surpassing outcomes reported in comparable Phase 2 trials of semaglutide and tirzepatide at equivalent timepoints. This data placed retatrutide among the most efficacious metabolic compounds yet studied in controlled clinical trials. Published in the New England Journal of Medicine.

Phase 3 TRIUMPH-4 (December 2025)

The first successful Phase 3 readout — a 68-week trial in 445 adults with obesity and knee osteoarthritis — reported 28.7% mean body weight reduction on the 12mg weekly dose (26.4% on 9mg, 2.1% on placebo). This established Phase 3-level efficacy for retatrutide's obesity-with-comorbidity indication.

Phase 3 TRANSCEND-T2D-1 (March 2026)

Retatrutide's first Phase 3 readout in type 2 diabetes. The 40-week trial delivered A1C reductions up to 2.0% and average weight loss up to 16.8% (36.6 lbs) on the 12mg dose, confirming efficacy extended to the T2D population.

Phase 3 TRIUMPH-1 (May 2026)

The pivotal 80-week obesity trial in 2,339 participants. Results showed weight loss of 17.6% (4mg), 23.7% (9mg), and 25.0% (12mg) vs 3.9% on placebo. Notably, 45.3% of participants on the 12mg dose lost more than 30% of body weight — an outcome historically associated with weight loss surgery.

Regulatory outlook

Seven additional Phase 3 readouts are expected before the end of 2026. Eli Lilly's New Drug Application is expected in the Q4 2026 to Q1 2027 window, with potential FDA approval in late 2027 to 2028. Clinical trial information is available through ClinicalTrials.gov retatrutide trials.

For a complete timeline of retatrutide's clinical development, see Retatrutide Clinical Trial Timeline: The Complete TRIUMPH Program Guide.

As of the time of writing, retatrutide remains an investigational compound. It has not received regulatory approval from Health Canada, the FDA, or any other agency.

Why Retatrutide Is Studied Alongside Other Metabolic Peptides

Researchers studying metabolic biology frequently examine retatrutide alongside compounds targeting different mechanisms — Tesamorelin for GH-axis comparisons, Semaglutide for within-class benchmarking, and MOTS-c for cellular energy metabolism. Each comparison illuminates distinct aspects of metabolic biology.

Tesamorelin — A GHRH analogue that specifically reduces visceral adipose tissue. Retatrutide and tesamorelin target fat loss via entirely different mechanisms (incretin/glucagon axis vs. growth hormone axis), making them complementary subjects in adipose tissue research.

Semaglutide / GLP-1 monoagonists — Retatrutide is frequently benchmarked against semaglutide in metabolic model research as a direct within-class comparison for the incremental effect of adding GIP and glucagon agonism.

MOTS-c — A mitochondrial peptide with distinct energy metabolism research relevance. Researchers interested in energy homeostasis at a cellular level may examine MOTS-c and retatrutide in complementary but mechanistically different frameworks.

For a broader comparison across the incretin class, see Retatrutide vs Tirzepatide vs Semaglutide: Complete Comparison.

Reconstitution Method

Retatrutide in research-grade lyophilized form is reconstituted using bacteriostatic water at concentrations typically ranging from 2 mg/mL to 5 mg/mL, following standard aseptic technique for peptide reconstitution. The specific concentration chosen depends on the research protocol's dispensing requirements.

Protocol

1. Wipe the tops of both the retatrutide vial and BAC water vial with an alcohol wipe. Allow to air dry.
2. Draw the required volume of BAC water into an insulin syringe.
3. Insert the needle through the retatrutide vial stopper at an angle.
4. Release BAC water slowly against the inner wall. Do not inject directly onto the powder.
5. Swirl gently — do not shake. Allow up to 2 minutes for complete dissolution.
6. The solution should be clear and colourless.

Concentration reference

BAC Water Added	Retatrutide Amount	Concentration
1ml	2mg	2mg/ml
2ml	5mg	2.5mg/ml
1ml	5mg	5mg/ml

For the full reconstitution and concentration calculation guide, see How to Reconstitute Peptides with BAC Water. Research-grade bacteriostatic water is available with USP-grade sterility standards.

Storage

State	Condition	Estimated Stability
Lyophilized powder	-20°C	Up to 24 months
Lyophilized powder	4°C	Up to 3 months
Reconstituted solution	4°C	28 days
Reconstituted solution	Room temperature	24 hours max

Protect from light and avoid freeze-thaw cycles of reconstituted solution. For a broader guide to peptide handling, see How to Store Research Peptides: A Complete Stability and Handling Guide.

Sourcing Retatrutide in Canada

Retatrutide has attracted significant research interest since publication of its Phase 2 and Phase 3 trial data, which has unfortunately driven a corresponding increase in low-quality supply in the research peptide market. Researchers sourcing retatrutide should apply rigorous criteria to ensure compound identity, purity, and supply chain integrity.

• Independent third-party COA from a named analytical laboratory — not self-reported purity
• HPLC or Mass Spectrometry verification confirming ≥98% purity and correct molecular identity
• Batch-specific testing — not a generic COA applied across multiple batches
• Canadian-based supplier for cold-chain integrity and elimination of customs risk

For detailed sourcing guidance specifically for Canadian research labs, see our Retatrutide Buying Guide.

View Retatrutide — Ships Same Day from Canada

Frequently Asked Questions

What does "GLP-3" mean?

GLP-3 is an informal designation in the research community reflecting retatrutide's position as the third generation of GLP-class metabolic peptides (after GLP-1 monoagonists and GLP-1/GIP dual agonists). It does not refer to a third GLP receptor — the official name for such a receptor does not exist in current pharmacology nomenclature.

How is retatrutide different from semaglutide?

Semaglutide is a GLP-1 receptor monoagonist. Retatrutide additionally agonizes the GIP receptor and the glucagon receptor, making it a triple agonist with distinct effects on energy expenditure and adipose tissue beyond what GLP-1 agonism alone produces. Phase 3 data through 2026 shows retatrutide produces approximately 25% body weight reduction at 80 weeks compared to semaglutide's ~15% at similar durations.

Has retatrutide been approved for human use?

No. As of mid-2026, retatrutide remains an investigational compound in Phase 3 clinical trials. It has not received regulatory approval from Health Canada, the FDA, or any other regulatory agency. Eli Lilly's NDA submission is expected Q4 2026 to Q1 2027, with potential FDA approval in late 2027 to 2028.

Is retatrutide available in Canada for research?

Yes. Research-grade retatrutide is available for purchase by qualified researchers in Canada. It is sold for in vitro and laboratory research use only — not for human or veterinary use.

What are the latest clinical trial results for retatrutide?

The three most recent Phase 3 readouts are: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial. Seven additional Phase 3 readouts are expected before end of 2026.

Summary

Retatrutide represents the current frontier of incretin-based metabolic research. Its triple receptor agonism — targeting GLP-1R, GIPR, and GcgR simultaneously — produces a metabolic profile that surpasses earlier GLP-class compounds in published clinical research across Phase 2 and Phase 3 trials. For Canadian researchers studying obesity biology, metabolic syndrome, NASH, and energy homeostasis, retatrutide is a mechanistically rich and actively investigated research subject.

[Shop Retatrutide (GLP-3)] [Shop BAC Water]

⚠️ Disclaimer: Retatrutide is sold by Emerald Peptides strictly for in vitro research and laboratory use. It is not approved by Health Canada or any regulatory agency for human or veterinary use. It is an investigational compound. By purchasing, the buyer confirms they are a qualified researcher using this compound in a legitimate research setting.